Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study to Evaluate RNK08954 in Participants With Advanced Gynecologic Malignancies Harboring the KRAS G12D Mutation

NCT07848893 is registered in ClinicalTrials.gov with Ranok Therapuetics Co. Ltd. as lead sponsor.

NCT NCT07848893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07848893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study to Evaluate RNK08954 in Participants With Advanced Gynecologic Malignancies Harboring the KRAS G12D Mutation
Lead sponsor
Ranok Therapuetics Co. Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
August 31, 2028
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gynecologic malignancies